Published on: February 3, 2016
Material fundraising to drive growth
Instem has announced a proposed £5m fundraising via the placing of 2.5m new shares. Monies raised will accelerate the group’s consolidation strategy and fund organic growth. The outlook for organic expansion remains favourable, as evidenced by record levels of potential new drugs in early stages of the R&D pipeline. Management has provided meaningful colour on the acquisition strategy, and we note the company’s solid track record of successful M&A.